Ark Genomic Revolution Ucits ETF AccumUSD (AAKG.DE) Price

Ark Genomic Revolution Ucits ETF AccumUSD is offered by ARK, a leading player in the field of passive investments.

The ISIN of Ark Genomic Revolution Ucits ETF AccumUSD is IE000O5M6XO1.

The total expense ratio of Ark Genomic Revolution Ucits ETF AccumUSD is 0.79%, which means that investors pay 79.00 EUR per 10,000 EUR in investment capital annually.

The ETF is listed in EUR.

European investors may incur additional costs for currency exchange and transaction fees.

Yes, Ark Genomic Revolution Ucits ETF AccumUSD complies with the EU UCITS investor protection directives.

Ark Genomic Revolution Ucits ETF AccumUSD is domiciled in IE.

The fund was launched on 4/12/2024.

The Ark Genomic Revolution Ucits ETF AccumUSD mainly invests in Topic companies.

The NAV of Ark Genomic Revolution Ucits ETF AccumUSD amounts to 4.42 M EUR.

The price-to-book ratio is 3.48.

Investments can be made through brokers or financial institutions that provide access to trading ETFs.

The ETF is traded on the stock exchange, similar to stocks.

Yes, the ETF can be held in a regular securities account.

The ETF is suitable for both short-term and long-term investment strategies, depending on the investor's goals.

The ETF is valued on a daily stock exchange basis.

Information on dividends should be requested from the provider's website or your broker.

The risks include market fluctuations, currency risks, and the risk associated with smaller companies.

The ETF is obligated to report regularly and transparently on its investments.

The performance can be viewed on Eulerpool or directly on the provider's website.

Further information can be found on the official website of the provider.